Saturday, March 15, 2025
1.3 C
London
HomeFinTechImmuron: Shares spike on FDA approval for Travelan IND application

Immuron: Shares spike on FDA approval for Travelan IND application

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...

Immuron Shares spike on FDA approval for Travelan IND application

  • Immuron’s (IMC) lands US Food and Drug Administration (FDA) approval for its investigational new drug application for its Travelan product
  • With the approval in hand, IMC can proceed with its clinical trial assessing the safety and efficacy of the drug to prevent infectious diarrhea
  • The company plans to enrol up to 60 healthy adults in the study, with half to receive a once-daily dose of 1200 milligrams of Travelan and half to receive a placebo
  • Recruitment is due to begin in the first half of the new year, with headline results from the trial expected to be reported by the end of 2023
  • The company shares are up 23.61 per cent and trading at 8.9 cents at 11:56 am AEDT

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories